As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

The Japanese cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this ...

AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and ...

Public health and health care delivery may seem to go hand in hand to the public they exist to serve. But partnerships for the public good often are complicated by a patchwork of elaborate ...

Non-cognitive skills: The hidden key to academic success. ScienceDaily . Retrieved September 19, 2024 from www.sciencedaily.com / releases / 2024 / 08 / 240826131236.htm ...

Shares in AstraZeneca dropped nearly 5 per cent on Tuesday after its failure to hit a target in trials for a next-generation ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Eltek Ltd. , a global manufacturer and supplier of technologically advanced solutions in the field of printed circuit boards, is pleased to announce the appointment of Tomer Segev as its new Vice ...

CJ-15314 is under development for the treatment of rheumatoid arthritis, psoriasis and atopic dermatitis. The drug candidate is administered orally as capsule and topically as ointment. The drug ...

Mohit Bansal, an analyst from Wells Fargo, maintained the Hold rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated ...

Late-breaking presentations in breast cancer at ESMO will include a proffered paper session featuring the primary results of the DESTINY-Breast12 phase 3b/4 trial evaluating ENHERTU in patients ...